Skip to main content
. 2016 Apr 28;173(11):1778–1792. doi: 10.1111/bph.13476

Figure 4.

Figure 4

RPC1063 treatment reduces ongoing disease symptoms in EAE. EAE was induced in mice by immunization with MOG35–55 peptide and at the first signs of clinical disease (limp tail) individual mice were randomized and dosed with test compound for 14 days. Clinical disease scores were assessed daily (A) and at the end of the study (B). Body weights (C) were assessed at the end of the study. The number of circulating lymphocytes was assessed by differential count 24 h after the final dose (D). n = 9–10 per group. Error bars represent SEM; *P < 0.05 by One‐way ANOVA.